170450-77-8

Basic information

• Product Name: (S)-4-benzyl-3-(3-phenylbutanoyl)oxazolidin-2-one
• Synonyms: (S)-4-benzyl-3-(3-phenylbutanoyl)oxazolidin-2-one
• CAS NO: 170450-77-8
• Molecular Weight: 323.392
• Mol File: 170450-77-8.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: (S)-4-benzyl-3-(3-phenylbutanoyl)oxazolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-benzyl-3-(3-phenylbutanoyl)oxazolidin-2-one(170450-77-8)
• EPA Substance Registry System: (S)-4-benzyl-3-(3-phenylbutanoyl)oxazolidin-2-one(170450-77-8)

Safety Data

• Hazardous Substances Data: 170450-77-8(Hazardous Substances Data)

Upstream product

• 1821-12-1 4-Phenylbutyric acid 
• 71-43-2 benzene 
• 2051-95-8 succinylbenzene 
• 90719-32-7 (S)-4-Benzyl-2-oxazolidinone 
• 18496-54-3 phenylbutyric acid chloride 
• 101711-90-4 (S)-4-benzyl-2-oxazolidinone lithium salt 

Downstream Products

• 170450-82-5 (2S,3R)-3-((S)-4-Benzyl-2-oxo-oxazolidine-3-carbonyl)-2-methyl-5-phenyl-pentanoic acid benzyl ester 
• 184844-16-4 (2S,3R)-3-((S)-4-Benzyl-2-oxo-oxazolidine-3-carbonyl)-2-hydroxy-2-methyl-5-phenyl-pentanoic acid methyl ester 
• 184844-17-5 (2R,3R)-3-((S)-4-Benzyl-2-oxo-oxazolidine-3-carbonyl)-2-hydroxy-2-methyl-5-phenyl-pentanoic acid methyl ester 
• 193814-54-9 (R)-4-((S)-4-Benzyl-2-oxo-oxazolidine-3-carbonyl)-6-phenyl-hexanoic acid tert-butyl ester 
• 186895-51-2 (S)-4-Benzyl-3-((S)-2-methyl-4-phenyl-butyryl)-oxazolidin-2-one 
• 188729-02-4 4(S)-benzyl-3-<2(R)-<(tert-butoxycarbonyl)methyl>-4-phenylbutanoyl>-2-oxazolidinone 
• 156109-58-9 mono-t-butyl 3(R)-phenethylsuccinate 
• 188729-04-6 (R)-3-[((S)-Methylcarbamoyl-phenyl-methyl)-carbamoyl]-5-phenyl-pentanoic acid 
• 188729-03-5 (R)-3-[((S)-Methylcarbamoyl-phenyl-methyl)-carbamoyl]-5-phenyl-pentanoic acid tert-butyl ester 
• 205526-94-9 N⁴-benzyloxy-N¹-(methylcarbamoyl-phenyl-methyl)-2-phenethyl-succinamide 
• 207686-11-1 (2S,3R)-2-Hydroxy-3-[(S)-2-(4-methoxy-phenyl)-1-methylcarbamoyl-ethylcarbamoyl]-2-methyl-5-phenyl-pentanoic acid 
• 207686-15-5 (2R,3R)-2-Hydroxy-3-[(S)-2-(4-methoxy-phenyl)-1-methylcarbamoyl-ethylcarbamoyl]-2-methyl-5-phenyl-pentanoic acid 
• 207686-04-2 (2S,3R)-2-Hydroxy-3-[(S)-2-(4-methoxy-phenyl)-1-methylcarbamoyl-ethylcarbamoyl]-2-methyl-5-phenyl-pentanoic acid methyl ester 
• 207686-08-6 (2R,3R)-2-Hydroxy-3-[(S)-2-(4-methoxy-phenyl)-1-methylcarbamoyl-ethylcarbamoyl]-2-methyl-5-phenyl-pentanoic acid methyl ester 

Relevant articles and documents

HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE

Disclosed are compounds having the formula: (I) wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.

HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE

Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.

Synthesis and SAR of succinamide peptidomimetic inhibitors of cathepsin S

Peptidic, non-covalent inhibitors of lysosomal cysteine protease cathepsin S (1 and 2) were investigated due to low oral bioavailability, leading to an improved series of peptidomimetic inhibitors. Utilizing phenyl succinamides as the P2 residue increased the oral exposure of this lead series of compounds, while retaining selective inhibition of the cathepsin S isoform. Concurrent investigation of the P1 and P2 subsites resulted in the discovery of several potent and selective inhibitors of cathepsin S with good pharmacokinetic properties due to the elimination of saturated aliphatic P2 residues.